| Drug General Information |
| Drug ID |
D06TRS
|
| Former ID |
DNC004856
|
| Drug Name |
3-(3-methylthiophen-2-yl)pyridine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C10H9NS
|
| Canonical SMILES |
CC1=C(SC=C1)C2=CN=CC=C2
|
| InChI |
1S/C10H9NS/c1-8-4-6-12-10(8)9-3-2-5-11-7-9/h2-7H,1H3
|
| InChIKey |
JIOQSJVEVFADJG-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
|
Linoleic acid metabolism
|
|
Retinol metabolism
|
|
Metabolism of xenobiotics by cytochrome P450
|
|
Drug metabolism - cytochrome P450
|
|
Drug metabolism - other enzymes
|
|
Metabolic pathways
|
|
Bile secretion
|
|
Chemical carcinogenesis
|
|
PathWhiz Pathway
|
Caffeine Metabolism
|
|
Retinol Metabolism
|
|
Reactome
|
Xenobiotics
|
|
Aflatoxin activation and detoxification
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Aflatoxin B1 metabolism
|
|
Estrogen metabolism
|
|
Benzo(a)pyrene metabolism
|
|
Tamoxifen metabolism
|
|
Tryptophan metabolism
|
|
Oxidation by Cytochrome P450
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Farnesoid X Receptor Pathway
|
|
Vitamin D Receptor Pathway
|
|
Felbamate Metabolism
|
|
Lidocaine metabolism
|
|
Nifedipine Activity
|
|
Colchicine Metabolic Pathway
|
|
Irinotecan Pathway
|
|
Drug Induction of Bile Acid Pathway
|
|
Fatty Acid Omega Oxidation
|
|
Codeine and Morphine Metabolism
|
| References |
| REF 1 | J Med Chem. 2006 Nov 30;49(24):6987-7001.Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. |
|---|
